Treatment of postmenopausal osteoporosis, patient perspectives &amp;ndash; focus on once yearly zoledronic acid

Carmona, Raj; Adachi, Rick

doi:10.2147/ppa.s3494

Cited by 9 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Any or a combination of these primarily occurred following the first infusion (31.6%). These progressively decreased with subsequent infusions; only 2.8% experienced these symptoms after the third infusion (16). In our study, the frequency of side effects diminished with repeated infusions.…”

Section: Discussionsupporting

confidence: 40%

See 1 more Smart Citation

Yıllık Zoledronik Asit İnfüzyonu Yapılan Osteoporoz Hastalarında Memnuniyet, Hasta Tercihi ve Yan Etkinin Değerlendirilmesi

Dilek¹,

Şahin²,

Erdem³

et al. 2017

Tod

View full text Add to dashboard Cite

Amaç: Bu çalışmada osteoporoz tedavisi için yıllık zoledronik asit (ZA) infüzyonu yapılan hastalarda memnuniyet, hasta tercihi ve yan etki değerlendirilmesinin yapılması amaçlanmıştır. Gereç ve Yöntem: Çalışmaya ZA infüzyonu yapılmış 59 hasta katıldı. Hastaların demografik ve osteoporoz özellikleri ve ZA infüzyon sayısı sorgulandı. Daha sonra hasta tercihinin sorgulanmasında yedi soruluk bir anket kullanıldı. Hasta genel memnuniyeti, ilacın uygulanması sırasındaki memnuniyet düzeyi, yaşam kalitesi üzerine etkileri Likert skalası ile değerlendirildi. Bulgular: Çalışmaya alınan 59 (50 kadın, 9 erkek) hastanın yaş ortalaması 68,49±8,65 yıl olarak bulundu. Hastaların %86,4'ü (51) aynı tedaviye devam etmek istediğini, %64,4'ü (36) uygulamanın fazlasıyla kolay olduğunu, %61'i (36) yaşam tarzı ile fazlasıyla uyumlu olduğunu bildirilmiştir. İlaca devam ya da kullanımında etkili en önemli faktörlerin yıllık kullanım kolaylığı ve hekimin önerisi olduğu görülmüştür. Hastaların %23,7'sinde (14) ilk infüzyonda hafif yan etkiler (miyalji, artralji, flu like sendrom, ateş, baş ağrısı ve kaşıntı) olduğu bildirilmiştir. ZA infüzyon uygulamasından hastaların %37,3'ünün (22) oldukça, %40,7'sinin (24) fazlasıyla memnun olduğunu bildirmiştir. İlacın yaşam kalitesine etkisi sorgulandığında hastaların %42,4'ü (25) oldukça, %37,3'ü (22) fazlasıyla etkili olduğunu belirtmiştir. Hastaların %47,5'i (28) ilk kez ZA infüzyonu yaptırırken, %52,5'i (31) birden fazla infüzyon (2-4) yaptırmıştı. İnfüzyon sayısındaki artışın yaşam kalitesi, memnuniyet ve hasta tercihini etkilemediği saptanmıştır. Sonuç: ZA infüzyonu hastalarda tercih edilen, memnuniyet düzeyi yüksek, yaşam kalitesini olumlu etkileyen uygulaması kolay ve yan etkileri tolere edilebilen bir tedavi yöntemidir. Anahtar kelimeler: Osteoporoz, zoledronik asit, hasta memnuniyeti, hasta tercihi, adherans, yan etki Evaluation of Patient Satisfaction, Preference and Side Effects after Annual Zoledronic Acid Infusion in Patients with Osteoporosis Yıllık Zoledronik Asit İnfüzyonu Yapılan Osteoporoz Hastalarında Memnuniyet, Hasta Tercihi ve Yan Etkinin DeğerlendirilmesiObjective: In this study it was aimed to evaluate the patient satisfaction, therapy preference and side-effect profile in patients who receive annual zoledronic acid (ZA) infusion. Materials and Methods:In this study, 59 patients who had ZA infusion were enrolled. Their demographic and osteoporosis characteristics and the number of received ZA infusions were recorded. A seven-item questionnaire was used to assess the patients' therapy preference. General patient satisfaction, satisfaction during ZA infusion and its effects on life quality were assessed with a Likert scale. Results:The mean age of the 59 patients (50 females, 9 males) was 68.49±8.65 years. Of the patients 86.4% (51) wanted to continue the same therapy, 64.4% (36) stated that the mode of administration was very convenient and 61% (36) stated that it was well-suited with their lifestyle. The most important factors for the continued usage were the annual administra...

show abstract

Section: Discussionsupporting

confidence: 40%

“…These data point to maximal benefit with maximum adherence. They also suggest that even with some degree of drug use, suboptimal adherence can lead to a total loss of any benefit (16). In our study, our compliance may help to reduce the risk of fracture.…”

Section: Discussionmentioning

confidence: 69%

Yıllık Zoledronik Asit İnfüzyonu Yapılan Osteoporoz Hastalarında Memnuniyet, Hasta Tercihi ve Yan Etkinin Değerlendirilmesi

Dilek¹,

Şahin²,

Erdem³

et al. 2017

Tod

View full text Add to dashboard Cite

show abstract

“…The US Surgeon General has indeed identified poor compliance with therapy as a major obstacle in the successful management of osteoporosis and reducing the risk of fractures 13. Patients prefer less frequent dosing regimens and intravenous (IV) infusion to the oral intake of bisphosphonates 10,14. These are now becoming available.…”

Section: Osteoporosis Medicationsmentioning

confidence: 99%

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass

Hamdy¹

2010

DDDT

View full text Add to dashboard Cite

The availability of a once-a-year zoledronic acid infusion heralds a new era in the management of osteoporosis. It virtually eliminates the problem of poor compliance with orally administered bisphosphonates and, because it bypasses the gastrointestinal tract, it is not associated with gastrointestinal side effects. Zoledronic acid is effective for the treatment and prevention of postmenopausal osteoporosis, and for the treatment of osteoporosis in men, and glucocorticoid-induced osteoporosis. When administered within three months of a hip fracture, it reduces mortality and the risk of subsequent fractures. It is remarkably free of serious adverse effects. After administration of the intravenous infusion, about 18% of bisphosphonate-naïve patients experience an acute-phase reaction, including low-grade temperature, aches, and pains. This is reduced to about 9% in those who have been treated with oral bisphosphonates, and is further reduced by the concomitant and subsequent administration of acetaminophen. The likelihood and magnitude of the acute-phase reaction is less after the second infusion. Other adverse effects are similar to those encountered with other bisphosphonates. Because it is mostly excreted by the kidneys, zoledronic acid should not be administered to patients with a creatinine clearance less than 35 mL/min. It should not be administered to patients with hypocalcemia.

show abstract

“…13 Persistence with osteoporosis treatment is known to be poor for many existing drugs, such as the OBPs. [14][15][16] It is likely that the 6-monthly administration in GP surgery or hospital clinic will encourage persistence with denosumab.…”

Section: Summary Of Submitted Clinical Evidencementioning

confidence: 99%

Denosumab for the Prevention of Osteoporotic Fractures in Post-Menopausal Women

et al. 2011

View full text Add to dashboard Cite

show abstract

Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid

Cited by 9 publications

References 18 publications

Yıllık Zoledronik Asit İnfüzyonu Yapılan Osteoporoz Hastalarında Memnuniyet, Hasta Tercihi ve Yan Etkinin Değerlendirilmesi

Yıllık Zoledronik Asit İnfüzyonu Yapılan Osteoporoz Hastalarında Memnuniyet, Hasta Tercihi ve Yan Etkinin Değerlendirilmesi

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass

Denosumab for the Prevention of Osteoporotic Fractures in Post-Menopausal Women

Contact Info

Product

Resources

About